Arrêt et réduction du tabac chez le patient souffrant de schizophrénie

Underner, M.; Perriot, J.; Brousse, Georges; Chazeron, Ingrid de; Schmitt, Andrea; Peiffer, G.; Harika‐Germaneau, Ghina; Jaafari, Nemat

doi:10.1016/j.encep.2019.04.067

L'Encéphale

2019

DOI: 10.1016/j.encep.2019.04.067

|View full text |Cite

Arrêt et réduction du tabac chez le patient souffrant de schizophrénie

M. Underner

J. Perriot

Georges Brousse³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 Evidence suggests that PwS can give up smoking with the help of pharmacological interventions such as varenicline, bupropion, and nicotine replacement therapy (NRT) either alone or in combination, [16][17][18][19] or along with behavioral interventions such as cognitive-behavioral therapy (CBT), motivational interviewing (MI), and behavioral counseling. 18,[20][21][22] A recent systematic review reported that at six months, the rate of smoking cessation among PwS using psychosocial interventions (11%-18%) was comparable to pharmacotherapy (12%-19%). 23 Psychosocial strategies have been considered to be important ingredients in addiction treatment.…”

mentioning

confidence: 99%

Development of a Personalized Tobacco Cessation Intervention Package (PTCIP) for Persons with Schizophrenia in India

Rajalu

Jayarajan

Muliyala

et al. 2022

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

Background: Among persons with schizophrenia (PwS), tobacco use is higher in comparison to the general population, contributing to greater morbidity and mortality. Pharmacological interventions combined with psychosocial interventions are effective in tobacco cessation. While the effectiveness of extant psychosocial interventions—when used in isolation—seems limited, developing better combinations of interventions could help treatment providers deliver tobacco cessation services to PwS at different stages of motivation to quit. We aimed to develop a personalized tobacco cessation intervention package (PTCIP) for PwS. Methods: The stage-based intervention package was developed through a systematic review of interventions for tobacco cessation, the authors’ clinical experience, and expert validation. The components of the intervention package, developed for PwS visiting the outpatient psychiatric department, were retained, removed, or added based on the content validity ratio (CVR). Results: The final components included brief advice, principles of motivational interviewing, psychoeducation, decisional balance matrix, positive reinforcement, offering various treatment options, personalized feedback using a smoking-risk calculator, and prediction of cardiovascular risk using the WHO package of essential noncommunicable disease (PEN). The delivery of the intervention package was refined based on pilot testing in eight participants. Conclusion: The tailored package was designed to be delivered by a mental health professional as a single comprehensive 40 min to 45 min face-to-face session, integrated with routine follow-up visits, followed by two telephonic conversations in the second and third week of the initial session. The package needs to be tested in a randomized controlled trial for its effectiveness.

show abstract

mentioning

confidence: 99%

Development of a Personalized Tobacco Cessation Intervention Package (PTCIP) for Persons with Schizophrenia in India

Rajalu

Jayarajan

Muliyala

et al. 2022

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

show abstract

Cigarette électronique chez les patients fumeurs présentant une pathologie psychotique. Revue de la littérature

Underner¹,

Perriot²,

Brousse³

et al. 2021

L'Encéphale

View full text Add to dashboard Cite

Major depression, sleep, hostility and body mass index are associated with impaired quality of life in schizophrenia. Results from the FACE-SZ cohort.

Fond

Korchia

Verville

et al. 2020

Journal of Affective Disorders

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Arrêt et réduction du tabac chez le patient souffrant de schizophrénie

Cited by 5 publications

References 71 publications

Development of a Personalized Tobacco Cessation Intervention Package (PTCIP) for Persons with Schizophrenia in India

Development of a Personalized Tobacco Cessation Intervention Package (PTCIP) for Persons with Schizophrenia in India

Cigarette électronique chez les patients fumeurs présentant une pathologie psychotique. Revue de la littérature

Major depression, sleep, hostility and body mass index are associated with impaired quality of life in schizophrenia. Results from the FACE-SZ cohort.

Contact Info

Product

Resources

About